Lyell Immunopharma, Inc. LYEL
9.85
(0.27)
(2.67%)
as of 25 Sep
- Market cap
- $248.0M
- P/E
- 0.0×
Follow LYEL
Growth Flags
show if company had growth for consecutive years,
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
7,235.91 | 14,614.52 | 14,155.89 | 12,157.93 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(10.38) | (16.31) | (11.40) | (9.68) | |
P/B ratio |
0.90 | 2.12 | 1.60 | 1.40 | |
Price to Tangible BV |
0.90 | 2.12 | 1.60 | 1.40 | |
EV/Sales |
(559.80) | 7,747.29 | 5,961.60 | 4,598.60 | |
EV/EBITDA |
0.07 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
0.14 | (1.86) | (1.38) | (0.93) | |
EV/FCF |
0.12 | (1.45) | (1.05) | (0.71) | |
Quick Ratio |
10.03 | 5.00 | 6.88 | 5.12 | |
Current Ratio |
10.30 | 5.28 | 7.23 | 5.36 | |
Net Debt/EBITDA |
8.95 | 1.96 | 5.93 | 4.44 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.74 | 0.23 | 1.59 | 0.76 | |
Capex/Depreciation |
0.13 | (31.02) | (0.06) | (0.18) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
187,813.33% | 869,983.33% | 1,830,200.00% | 988,100.00% | |
Selling, General and Administrative Expense of Revenue |
71,246.67% | 176,933.33% | 477,750.00% | 239,400.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
34,880.00% | 426,150.00% | 214,750.00% | 113,300.00% | |
Graham Net Nets |
0.84 | 0.32 | 0.43 | 0.41 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(141.75%) | (52.96%) | (68.79%) | (91.32%) | |
Free Cash Flow Yield |
(66.27%) | (36.44%) | (39.95%) | (53.27%) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.56) | (1.89) | (1.76) | (1.45) | |
Capex per Share |
0.01 | (2.43) | 0.00 | (0.01) | |
Free Cash Flow per Share |
(1.55) | (4.31) | (1.76) | (1.46) | |
Cash per Share |
17.50 | 14.46 | 11.61 | 8.74 | |
Shareholders Equity per Share |
18.02 | 14.52 | 12.51 | 10.01 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
18.02 | 14.52 | 12.51 | 10.01 | |
Free Cash Flow |
(28.38) | (73.73) | (38.60) | (34.17) | |
Working Capital |
296.32 | 211.53 | 230.36 | 173.67 | |
Capital Expenditures |
0.20 | (41.47) | (0.09) | (0.25) | |
Net Current Asset Value |
249.36 | 169.09 | 190.34 | 136.20 | |
EV/EBIT |
0.07 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
(13.40) | 6,912.50 | 44.50 | 62.75 | |
Net Profit Margin |
(258,973.33%) | (2,345,383.33%) | (1,207,650.00%) | (1,118,875.00%) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
3.08 | 4.13 | 4.60 | 3.63 | |
Average Assets |
513.59 | 415.46 | 390.21 | 348.30 | |
Average Common Equity |
429.91 | 315.51 | 305.09 | 266.37 |
Columns are period end dates